Publication | Closed Access
Infertility: Composition of commercial gonadotrophin preparations extracted from human post-menopausal urine: characterization of non-gonadotrophin proteins
88
Citations
0
References
1994
Year
FertilityReproductive HealthGynecologyPathologyHuman Post-menopausal UrineReproductive BiologyNon-gonadotrophin ProteinsGonadotrophin PreparationsReproductive EndocrinologyReproductive PhysiologyCommercial Gonadotrophin PreparationsFemale InfertilityBioanalysisReproductive MedicinePublic HealthProteomicsMetrodin HpLow PurityInfertilityAndrologyEndocrinologyOvarian HormoneHuman ReproductionUrologyMedicineReproductive Hormone
Gonadotrophin preparations extracted from post-menopausal urine are of low purity and the major protein components are not gonadotrophins. A study was undertaken to identify some of these non-gonadotrophin proteins present in the extracted human urinary gonadotrophin preparations that are commercially available, i.e. Humegon (Organon), HMG Massone (Massone), Metrodin (Serono), Metrodin HP (Serono), Pergonal (Serono) and Progonadyl (Elea). As revealed by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) with Coomassie blue staining and Western blotting analysis, these products had electrophoretic protein profiles which differed in the amounts and species of proteins present. With the exception of Metrodin HP, all the other preparations tested contained tumour necrosis factor binding protein-I, transferrin, and immunoglobulin-related proteins. Some of the products contained in addition: urokinase, Tamm-Horsfall glycoprotein and epidermal growth factor. Recently, a highly purified human urinary follicle stimulating hormone (FSH) preparation (Metrodin HP) became available. In this preparation human FSH represents > 95% of the total proteins (approximately 10,000 IU of FSH/mg of protein). Metrodin HP was demonstrated to be the purest preparation tested, with none of the above-mentioned contaminants detected.